|Dr. Paula Ragan||Founder, CEO, Pres, Sec. & Director||N/A||N/A||1971|
|Dr. Renato T. Skerlj Ph.D.||Founder and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Adam S. Mostafa||CFO, Treasurer & Assistant Sec.||N/A||N/A||1980|
|Ms. Ronny Mosston||VP of HR||N/A||N/A||N/A|
|Dr. Robert David Arbeit M.D.||Sr. VP of Clinical Devel. and Translational Research||N/A||N/A||1948|
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
X4 Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.